Cure8 news brief
The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for patients not responding to current monotherapies.
Adults with moderate-to-severe Crohn's disease (including those who failed prior biologics), IBD clinicians, and researchers studying combination biologic therapies and biomarkers.
AbbVie's announcement summarizes a 300-patient, open-label Phase 2a platform study (TARGET-CD) comparing ABBV-466 to risankizumab and trosunilimab monotherapy.
The primary endpoint was endoscopic remission at Week 12; ABBV-466 had a larger proportion of patients meeting that endpoint at Weeks 12 and 24, and gene expression analyses reported epithelial repair and tissue remodeling with the combo.
The study population included many patients who had failed prior advanced therapies, which the company highlights as reflecting a real-world, treatment-experienced group. Safety events (serious adverse events) were reported at similar rates across arms through Week 24.
These results were released as a company press release and will be presented as a late-breaking abstract at UEGW; the full presentation and peer-reviewed data will provide needed detail on methods, statistical analyses, and independent review.
Results come from an open-label Phase 2a company press release and will be presented at UEGW; peer-reviewed publication and full trial data are needed to confirm benefit and safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...
